SLNSilence Therapeutics Plc - ADR

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that management will participate in an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026...

Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Curtis Rambaran, MD, Chief Medical Officer of Silence Therapeutics, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor...

Silence Therapeutics plc, Nasdaq: SLN (Silence or the Company), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the...

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) was the recipient of a large increase in short interest in April. As of April 15th, there was short interest totaling 2,075,273...

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the stock...

Silence Therapeutics (NASDAQ:SLN) Trading Down 1.8% - Here's Why...

Silence Therapeutics (SLN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven brokerages that are presently covering the...

Jefferies Financial Group raised shares of Silence Therapeutics to a "strong-buy" rating in a report on Wednesday...